Blood Research最新文献

{"title":"MicroRNA-765 is upregulated in myelodysplastic syndromes and induces apoptosis via PLP2 inhibition in leukemia cells.","authors":"Seong-Ho Kang,&nbsp;Ji Seon Choi","doi":"10.5045/br.2023.2023097","DOIUrl":"10.5045/br.2023.2023097","url":null,"abstract":"<p><strong>Background: </strong>Epigenetic studies, particularly research on microRNA (miRNA), have flourished. The abnormal expression of miRNA contributes to the development of hematologic malignancies. miR-765 has been reported to inhibit cell proliferation by downregulating proteolipid protein 2 (PLP2), which causes apoptosis. We investigated miR-765 dysregulation in myelodysplastic syndromes (MDS).</p><p><strong>Methods: </strong>We compared the expression profiles of miR-765 in 65 patients with MDS and 11 controls. Cell proliferation and apoptosis assays were performed to determine the <i>in vitro</i> effects of miR-765 on leukemia cells transfected with the miR-765 mimic. Reverse transcription quantitative PCR (RT-qPCR) and western blotting were performed to examine the targets of miR-765.</p><p><strong>Results: </strong>We found that miR-765 levels were upregulated 10.2-fold in patients with MDS compared to controls. In refractory cytopenia with multilineage dysplasia, the percentage of patients with elevated miR-765 levels was significantly higher than in other forms of MDS. Experiments with leukemia cells revealed that transfection with a miR-765 mimic inhibited cell proliferation and induced apoptosis. RT-qPCR and western blotting demonstrated that the target of miR-765 was PLP2.</p><p><strong>Conclusion: </strong>These findings imply that upregulation of miR-765 induces apoptosis via downregulation of PLP2 and may have a role in MDS pathogenesis.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e7/7a/br-58-3-133.PMC10548289.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9930594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concomitant ruxolitinib with cytarabine-based induction chemotherapy in secondary acute myeloid leukemia evolving from myeloproliferative neoplasm.","authors":"Dong Hyun Kim,&nbsp;Ja Min Byun,&nbsp;Dong-Yeop Shin,&nbsp;Inho Kim,&nbsp;Sung-Soo Yoon,&nbsp;Youngil Koh","doi":"10.5045/br.2023.2023136","DOIUrl":"10.5045/br.2023.2023136","url":null,"abstract":"Age 62 74 Gender F M MPN type Essential thrombocythemia Polycythemia vera AML diagnosis Feb 2019 Mar 2019 JAK2 status Negative Positive Other molecular status Complex karyotype, TP53, ROS1, FGFR4 mutations Not assessed Treatment 5+2 induction chemotherapy with ruxolitinib 5+2 induction chemotherapy with ruxolitinib Response to induction Complete remission Partial remission Response to consolidation Not assessed (EOT) Not assessed (EOT) EOT reason Septic pneumonia Deteriorated condition Duration of response 3 months + 24 months + OS 3 months 24 months + Outcome Deceased Medically stable after EOT","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ff/9b/br-58-3-155.PMC10548284.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10423129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistent polyclonal B-cell lymphocytosis with buttock-like cells mimicking follicular lymphoma.","authors":"Fnu Aakash,&nbsp;Sa A Wang,&nbsp;Karan Saluja,&nbsp;Beenu Thakral","doi":"10.5045/br.2023.2023116","DOIUrl":"10.5045/br.2023.2023116","url":null,"abstract":"A 52-year-old woman was found to have leukocytosis [19.4×10 9 /L (range, 4 – 11)] with absolute lymphocytosis [5.8×10 9 /L (range, 1 – 4.8)] for ∼ 1 year. Peripheral blood (PB) showed circulating atypical, binucleated and clefted lymphocytes mimicking “buttock cells” of follicular lymphoma. PB flow cytometry (FC) showed polytypic B-cell lymphocytosis (64.4%) expressing CD19 + CD20 + CD27 + IgM + and CD5 - CD10 - CD38 - . No cutaneous lesions were noted. A staging bone marrow showed no evidence of lymphoma. Cytogenetics showed a normal female karyotype. Serum IgM levels were increased [8.4 g/L (range, 0.35 – 2.4)], with normal IgA and IgG levels. Serum protein electrophoresis and immunofixation studies showed no M-protein. PET-CT showed no lymphadenopathy or hepatosplenomegaly. She had 30-years smoking history. Based on the above findings, persistent polyclonal B ‐ cell lymphocytosis (PPBL) was diagnosed. PPBL is a benign proliferation of memory B-cells in adult women with longstanding smoking history. Exact pathogenesis of PPBL is not known, potential mechanisms include defect in CD40 activation pathway or expansion of functional CD27 + memory B-cells. About 90% of PPBL cases are HLA-DR7-positive","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/14/8a/br-58-3-125.PMC10548282.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9912193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hairy cell leukemia presenting as a pleural mass without leukemic component: a case report.","authors":"Ahmad Alshomrani,&nbsp;Jeffrey J Cannatella,&nbsp;Hina Qureishi","doi":"10.5045/br.2023.2023114","DOIUrl":"10.5045/br.2023.2023114","url":null,"abstract":"that analysis of 16S ribosomal RNA from the gut microbiome can be used to elucidate its effect on patient outcomes after transplantation [15]. Future studies should focus on the molecular mechanisms using metabolomic analyses. In summary, FMT shows promise for restoring microbial diversity and treating aGVHD in patients undergoing allo-HSCT. However, FMT remains experimental and the most effective route of administration, product formulation, volume, and frequency of the procedure has not yet been established. Further studies are required to evaluate the potential benefits of FMT in patients with steroid-refractory acute GVHD.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4d/77/br-58-3-148.PMC10548290.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10423127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ABO blood group and rhesus factor association with inpatient COVID-19 mortality and severity: a two-year retrospective review.","authors":"Alexander T Phan,&nbsp;Ari A Ucar,&nbsp;Aldin Malkoc,&nbsp;Janie Hu,&nbsp;Luke Buxton,&nbsp;Alan W Tseng,&nbsp;Fanglong Dong,&nbsp;Julie P T Nguyễn,&nbsp;Arnav P Modi,&nbsp;Ojas Deshpande,&nbsp;Johnson Lay,&nbsp;Andrew Ku,&nbsp;Dotun Ogunyemi,&nbsp;Sarkis Arabian","doi":"10.5045/br.2023.2023122","DOIUrl":"https://doi.org/10.5045/br.2023.2023122","url":null,"abstract":"<p><strong>Background: </strong>Early reports have indicated a relationship between ABO and rhesus blood group types and infection with SARS-CoV-2. We aim to examine blood group type associations with COVID-19 mortality and disease severity.</p><p><strong>Methods: </strong>This is a retrospective chart review of patients ages 18 years or older admitted to the hospital with COVID-19 between January 2020 and December 2021. The primary outcome was COVID-19 mortality with respect to ABO blood group type. The secondary outcomes were 1. Severity of COVID-19 with respect to ABO blood group type, and 2. Rhesus factor association with COVID-19 mortality and disease severity. Disease severity was defined by degree of supplemental oxygen requirements (ambient air, low-flow, high-flow, non-invasive mechanical ventilation, and invasive mechanical ventilation).</p><p><strong>Results: </strong>The blood type was collected on 596 patients with more than half (54%, N=322) being O+. The ABO blood type alone was not statistically associated with mortality (P=0.405), while the RH blood type was statistically associated with mortality (<i>P</i><0.001). There was statistically significant association between combined ABO and RH blood type and mortality (<i>P</i>=0.014). Out of the mortality group, the O+ group had the highest mortality (52.3%), followed by A+ (22.8%). The combined ABO and RH blood type was statistically significantly associated with degree of supplemental oxygen requirements (<i>P</i>=0.005). The Kaplan-Meier curve demonstrated that Rh- patients had increased mortality.</p><p><strong>Conclusion: </strong>ABO blood type is not associated with COVID-19 severity and mortality. Rhesus factor status is associated with COVID-19 severity and mortality. Rhesus negative patients were associated with increased mortality risk.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fc/2b/br-58-3-138.PMC10548287.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41170202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atypical posterior reversible encephalopathy syndrome secondary to dasatinib.","authors":"Amiya Ranjan Nayak,&nbsp;Deepika Yadav,&nbsp;Priyanka Naranje,&nbsp;Jasmita Dass,&nbsp;Pradeep Kumar,&nbsp;Mukul Aggarwal","doi":"10.5045/br.2023.2023057","DOIUrl":"https://doi.org/10.5045/br.2023.2023057","url":null,"abstract":"with skin involvement (proven by skin biopsy) has been reported twice. Other differential diagnoses of HSTCL include aggressive natural killer cell leukemia (typically negative for surface CD3 on flow cytometry) and T-lymphoblastic leukemia [dim expression of CD45 and surface CD3 with expression of immaturity markers (TdT/CD34/CD1a)] [4, 6, 8]. The disease has an aggressive course, and most cases will relapse. Moreover, there is no known optimal therapy [1, 2, 7]. With conventional chemotherapy, complete remission is uncommon, and most patients die within two years of diagnosis [5, 9]. Long-term remission can be achieved by allogeneic stem cell transplantation, and studies have suggested that both autologous and allogeneic transplants may confer a potential cure for the disease with an estimated 3 years overall survival after allogeneic transplantation of 56% [2, 8]. One major limitation regarding staging and assessing the extent of lymphoma is the unavailability of bone and PET scans for the patient at diagnosis, which makes assessment of response for chemotherapy and evaluation for achievement of remission challenging.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/90/66/br-58-3-161.PMC10548285.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41152099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venetoclax-azacitidine as salvage therapy for relapsed mixed phenotype acute leukemia after a second allogeneic hematopoietic stem cell transplantation: a case report.","authors":"Sabrine Mekni,&nbsp;Rimmel Yosra Kanoun,&nbsp;Saloua Ladeb,&nbsp;Dorra Belloumi,&nbsp;Nour Ben Abdeljelil,&nbsp;Tarek Ben Othman","doi":"10.5045/br.2023.2023061","DOIUrl":"https://doi.org/10.5045/br.2023.2023061","url":null,"abstract":"TO THE EDITOR: Mixed phenotype acute leukemia (MPAL) is rare, accounting for approximately 1–4% of acute leukemia (AL) cases [1]. Induction therapy for these cases is often based on acute lymphocytic leukemia (ALL) treatment protocols, followed by allogeneic stem cell transplantation (ASCT). However, post-ASCT relapse after ASCT remains the primary cause of treatment failure. The median overall survival (OS) of patients who relapse after ASCT is extremely poor, with a median 3-year survival rate ranging between 9% and 11% [2]. Recent studies have reported better survival rates with a combination of venetoclax (VEN) and hypomethylating agents (HMA). Here, we describe the case of a 36-year-old patient with B/T MPAL who developed medullary relapse after 2 ASCTs and was successfully treated with VEN and azacitidine (VEN-AZA).","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/28/08/br-58-2-118.PMC10310488.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10111922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A survey evaluating hematology physicians’ perspectives on central nervous system prophylaxis.","authors":"Ufuk Demirci,&nbsp;Meltem Kurt Yüksel,&nbsp;Hakki Onur Kırkızlar,&nbsp;Elif Birtaş Ateşoğlu,&nbsp;Özgür Mehtap,&nbsp;Ozan Salim,&nbsp;Ahmet Muzaffer Demir,&nbsp;Olga Meltem Akay","doi":"10.5045/br.2023.2023066","DOIUrl":"https://doi.org/10.5045/br.2023.2023066","url":null,"abstract":"<p><strong>Background: </strong>Central nervous system (CNS) prophylactic options for diffuse large B-cell lymphoma (DLBCL) are administered differently in most centers. Unfortunately, there is still not a consensus on which patients, which regimen, for how many cycles, and when prophylaxis should be administered. Thus, this remains an unmet clinical need.</p><p><strong>Methods: </strong>We administered a survey study under the Lymphoma Scientific Subcommittee of the Turkish Society of Haematology. The questions were directed to hematologists through the monkey survey system.</p><p><strong>Results: </strong>The CNS International Prognostic Index score is a factor that clinicians frequently use when deciding on prophylaxis and is considered reliable. Although the perspective on anatomical risk factors is similar to that reported in the literature, breast involvement is still considered a critical risk factor in Turkey. Participants considered double or triple hit and double/triple expressor lymphoma as significant risk factors. Various methods have been used to demonstrate CNS relapses. Intrathecal prophylaxis is the preferred method.</p><p><strong>Conclusion: </strong>There are diverse methodological and technical ideas. The controversial results reported in the literature on the effectiveness of CNS prophylaxis may explain this finding. Although CNS prophylactic methods for patients with DLBCL are still controversial, the effect of secondary CNS involvement on survival is inevitable. Standard practices followed by national guidelines may be effective in reducing the variety of application methods and creating homogeneous results for efficacy and survival follow-up studies.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/99/6a/br-58-2-99.PMC10310485.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9738278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study.","authors":"Ja Min Byun,&nbsp;Sung-Soo Park,&nbsp;Sung-Soo Yoon,&nbsp;Ari Ahn,&nbsp;Myungshin Kim,&nbsp;Jung Yeon Lee,&nbsp;Young-Woo Jeon,&nbsp;Seung-Hwan Shin,&nbsp;Seung-Ah Yahng,&nbsp;Youngil Koh,&nbsp;Chang-Ki Min","doi":"10.5045/br.2023.2023005","DOIUrl":"https://doi.org/10.5045/br.2023.2023005","url":null,"abstract":"<p><strong>Background: </strong>The goal of induction therapy for multiple myeloma (MM) is to achieve adequate disease control. Current guidelines favor triplet (bortezomib-lenalidomide-dexamethasone; VRd) or quadruplet regimens (daratumumab, bortezomib-thalidomide-dexamethasone; D-VTd). In the absence of a direct comparison between two treatment regimens, we conducted this study to compare the outcomes and safety of VRd and D-VTd.</p><p><strong>Methods: </strong>Newly diagnosed MM patients aged ＞18 years who underwent induction therapy followed by autologous stem cell transplantation (ASCT) between November 2020 and December 2021 were identified. Finally, patients with VRd (N=37) and those with D-VTd (N=43) were enrolled.</p><p><strong>Results: </strong>After induction, 10.8% of the VRd group showed stringent complete remission (sCR), 21.6% showed complete response (CR), 35.1% showed very good partial response (VGPR), and 32.4% showed partial response (PR). Of the D-VTd group, 9.3% showed sCR, 34.9% CR, 48.8% VGPR, and 4.2% PR (VGPR or better: 67.6% in VRd vs. 93% in D-VTd, P=0.004). After ASCT, 68.6% of the VRd group showed CR or sCR, while 90.5% of the D-VTd group showed CR or sCR (P=0.016). VRd was associated with an increased incidence of skin rash (P=0.044). Other than rashes, there were no significant differences in terms of adverse events between the two groups.</p><p><strong>Conclusion: </strong>Our study supports the use of a front-line quadruplet induction regimen containing a CD38 monoclonal antibody for transplant-eligible patients with newly diagnosed MM.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a0/ef/br-58-2-83.PMC10310489.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10092905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of plasmapheresis in neutropenic patients suffering from cytokine storm because of severe COVID-19 infection.","authors":"Alireza Sadeghi,&nbsp;Somayeh Sadeghi,&nbsp;Mohammad Saleh Peikar,&nbsp;Maryam Yazdi,&nbsp;Mehran Sharifi,&nbsp;Safie Ghafel,&nbsp;Farzin Khorvash,&nbsp;Behrooz Ataei,&nbsp;Mohammad Reza Safavi,&nbsp;Elahe Nasri","doi":"10.5045/br.2023.2022201","DOIUrl":"https://doi.org/10.5045/br.2023.2022201","url":null,"abstract":"<p><strong>Background: </strong>With the emergence of the coronavirus disease 2019 (COVID-19) and inability of healthcare systems to control the disease, various therapeutic theories with controversial responses have been proposed. Plasmapheresis was administered as a medication. However, the knowledge of its efficacy and indications is inadequate. This study evaluated the use of plasmapheresis in critically ill patients with cancer.</p><p><strong>Methods: </strong>This randomized clinical trial was conducted on 86 patients with malignancies, including a control group (N=41) and an intervention group (N=45) with severe COVID-19 during 2020-21. Both groups were treated with routine medications for COVID-19 management according to national guidelines, and plasmapheresis was applied to the intervention group. C-reactive protein (CRP), D-dimer, ferritin, lactate dehydrogenase, hemoglobin, and white blood cell, polymorphonuclear, lymphocyte, and platelet levels were measured at admission and at the end of plasmapheresis. Other variables included neutrophil recovery, intensive care unit admission, intubation requirements, length of hospital stay, and hospitalization outcomes.</p><p><strong>Results: </strong>CR<i>P</i>(<i>P</i><0.001), D-dimer (<i>P</i><0.001), ferritin (<i>P</i>=0.039), and hemoglobin (<i>P</i>=0.006) levels were significantly different between the groups after the intervention. Neutrophil recovery was remarkably higher in the case than in the control group (<i>P</i><0.001). However, plasmapheresis did not affect the length of hospital stay (P=0.076), which could have significantly increased survival rates (<i>P</i><0.001).</p><p><strong>Conclusion: </strong>Based on the study findings, plasmapheresis led to a significant improvement in laboratory markers and survival rate in patients with severe COVID-19. These findings reinforce the value of plasmapheresis in cancer patients as a critical population suffering from neutropenia and insufficient immune responses.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9c/b7/br-58-2-91.PMC10310491.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10110839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}